Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States

Figures & data

Figure 1. PMPM cost with and without belumosudil – payer population.

Figure 2. PMPM cost with and without belumosudil – National population.

Table 1. Annual budget impact and absolute cost change – payer population.

	2021	2022	2023	2024	2025	2026
Excluding Belumosudil	$32.39	$48.96	$54.00	$68.91	$71.62	$73.20
Including Belumosudil	$32.39	$47.41	$51.21	$64.01	$66.70	$68.33
% Change	0.0%	–3.2%	–5.2%	–7.1%	–6.9%	–6.7%
Absolute Change	$0	–$1.54	–$2.79	–$4.90	–$4.93	–$4.87
Total cGVHD diagnosed patients	398	476	507	522	534	539
Treated cGVHD population	378	452	481	495	507	512

Millions of USD.

Table 2. Annual budget impact and absolute cost change – National population.

	2021	2022	2023	2024	2025	2026
Excluding Belumosudil	$1,003	$1,533	$1,695	$2,180	$2,268	$2,321
Including Belumosudil	$1,003	$1,491	$1,620	$2,049	$2,138	$2,192
% Change	0.0%	–2.7%	–4.4%	–6.0%	–5.8%	–5.5%
Absolute Change	$0	–$41.56	–$74.85	–$130.84	–$130.93	–$128.75
Total cGVHD diagnosed patients	13,182	15,772	16,791	17,287	17,703	17,855
Treated cGVHD population	12,523	14,984	15,951	16,423	16,818	16,962

Millions of USD.

Figure 3. Tornado diagram for top influencers of cost savings (±10% ranges) – payer population.

Figure 4. Tornado diagram for top influencers of cost savings (±10% ranges) – National population.

Figure 5. Budget percent change in 2026 with adoption of belumosudil with ibrutinib and ruxolitinib reduction.

Figure 6. PMPM costs of Belumosudil in 2026 with ibrutinib and ruxolitinib reduction.

Figure 7. Budget percent change in 2026 with adoption of belumosudil with ruxolitinib reduction only.

Figure 8. PMPM costs of belumosudil in 2026 with ruxolitinib reduction only.

Figure 9. Budget percent change in 2026 with adoption of belumosudil with ibrutinib reduction only.

Figure 10. PMPM costs of belumosudil in 2026 with ibrutinib reduction only.